Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)
Ruth Mary De Tute , Neil Rabin , James D Cavenagh , Guy Pratt
Blood 130 1864 -1864
2
2017
Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial
Mark T Drayson , Amy L Sherborne , Walter M Gregory , Martin F Kaiser
Blood 130 1767 -1767
2
2017
Assessment of Anti-Bacterial Antibodies in Multiple Myeloma Patients at Disease Presentation and in Response to Therapy: Implication for Patient Management
Mark T Drayson , Jennifer Lj Heaney , Stella Bowcock , Helen Higgins
Blood 130 3036 -3036
2017
Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia
Stephanie Watson , Craig E Hughes , Michael G Tomlinson , Steve P Watson
Blood 130 1030 -1030
2017
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
Mark T Drayson , Stella Bowcock , Helen Higgins , Guy Pratt
Blood 130 903 -903
16
2017
A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study
Claire Roddie , Jonathan Sive , Matthew J. Streetly , James D Cavenagh
Blood 130 267 -267
2017
Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis
Michael P Lunn , Jindriska Lindsay , Charalampia Kyriakou , Charalampia Kyriakou
Blood 136 1 -2
2020
Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing
Dipti Talaulikar , Dipti Talaulikar , Marie José Kersten , Mark Bishton
Blood 136 10 -11
1
2020
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.
David J. Allsup , David J. Allsup , Francesco Forconi , Christopher Fegan
Nature Communications 12 ( 1) 665 -665
2021
PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity.
Jianmin Zuo , Guy Pratt , Guy Pratt , Helen M. Parry
PLOS Pathogens 17 ( 3)
2021
Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients
Mark T Drayson , Stella Bowcock , Helen Higgins , Janet Dunn
Blood 130 2132 -2132
2017
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.
Christina Messiou , Martin Kaiser , Samantha Hinsley , Sarah Brown
BMJ Open 11 ( 3)
2021
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline
Jonathan Sive , Guy Pratt , Majid Kazmi , Dean Smith
British Journal of Haematology 193 ( 2) 245 -268
16
2021
Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia
Christopher Fegan , Mariappan Premanathan , Ian A. Brewis , Guy Pratt
Electronic Journal of Biotechnology 52 1 -12
2021
BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia
Francesco Forconi , Andy Rawstron , Ceri Oldreive , Tatjana Stankovic
Blood 130 3004 -3004
2017
Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia
David Allsup , Wei Yu Lin , Sarah Elizabeth Fordham , Nicola Sunter
Blood 134 1740 -1740
1
2019
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
James A L Fenton , Guy Pratt , Andy C Rawstron , Kathryn Sibley
Oncogene 22 ( 7) 1103 -1113
20
2003
CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response
Ceri E Oldreive , Victoria J Weston , Paul AH Moss , Guy Pratt
Blood 116 ( 21) 2439 -2439
2010
Immunologically Targeting the Leukaemia Phosphoproteome
Hugo De La Peña , Thomas Butler , Hsing-Wen Huang , Toral Jakhira
Blood 116 ( 21) 1016 -1016
2010
Increased Frequency of Constitutional PathogenicATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role.
Tatjana Stankovic , Belinda Austen , Guy Pratt , Anna Skowronska
Blood 114 ( 22) 1250 -1250
2009